Korro Bio (KRRO) Competitors $20.04 -0.51 (-2.48%) Closing price 04:00 PM EasternExtended Trading$20.02 -0.02 (-0.07%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KRRO vs. TNGX, BGM, MNMD, PHAT, AMLX, DAWN, PROK, DNTH, GHRS, and MRVIShould you be buying Korro Bio stock or one of its competitors? The main competitors of Korro Bio include Tango Therapeutics (TNGX), BGM Group (BGM), Mind Medicine (MindMed) (MNMD), Phathom Pharmaceuticals (PHAT), Amylyx Pharmaceuticals (AMLX), Day One Biopharmaceuticals (DAWN), ProKidney (PROK), Dianthus Therapeutics (DNTH), GH Research (GHRS), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical products" industry. Korro Bio vs. Its Competitors Tango Therapeutics BGM Group Mind Medicine (MindMed) Phathom Pharmaceuticals Amylyx Pharmaceuticals Day One Biopharmaceuticals ProKidney Dianthus Therapeutics GH Research Maravai LifeSciences Tango Therapeutics (NASDAQ:TNGX) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, earnings, valuation, media sentiment, dividends and analyst recommendations. Which has stronger valuation & earnings, TNGX or KRRO? Korro Bio has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTango Therapeutics$42.07M18.25-$130.30M-$1.33-5.19Korro Bio$6.28M29.96-$83.58M-$9.75-2.06 Does the media favor TNGX or KRRO? In the previous week, Korro Bio had 14 more articles in the media than Tango Therapeutics. MarketBeat recorded 20 mentions for Korro Bio and 6 mentions for Tango Therapeutics. Korro Bio's average media sentiment score of 0.15 beat Tango Therapeutics' score of -0.05 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 7 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of TNGX or KRRO? 79.0% of Tango Therapeutics shares are owned by institutional investors. Comparatively, 13.2% of Korro Bio shares are owned by institutional investors. 7.5% of Tango Therapeutics shares are owned by insiders. Comparatively, 4.6% of Korro Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is TNGX or KRRO more profitable? Korro Bio has a net margin of 0.00% compared to Tango Therapeutics' net margin of -599.11%. Korro Bio's return on equity of -61.51% beat Tango Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tango Therapeutics-599.11% -79.72% -49.30% Korro Bio N/A -61.51%-42.87% Do analysts prefer TNGX or KRRO? Tango Therapeutics currently has a consensus target price of $10.50, suggesting a potential upside of 52.17%. Korro Bio has a consensus target price of $86.83, suggesting a potential upside of 333.30%. Given Korro Bio's stronger consensus rating and higher possible upside, analysts clearly believe Korro Bio is more favorable than Tango Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tango Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00Korro Bio 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has more volatility and risk, TNGX or KRRO? Tango Therapeutics has a beta of 1.64, meaning that its share price is 64% more volatile than the S&P 500. Comparatively, Korro Bio has a beta of 2.51, meaning that its share price is 151% more volatile than the S&P 500. SummaryKorro Bio beats Tango Therapeutics on 12 of the 16 factors compared between the two stocks. Get Korro Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for KRRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KRRO vs. The Competition Export to ExcelMetricKorro BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$188.20M$2.80B$5.82B$9.73BDividend YieldN/A1.66%3.84%4.09%P/E Ratio-2.0622.6131.1525.96Price / Sales29.96751.86475.15122.97Price / CashN/A173.2237.1558.38Price / Book1.635.869.116.39Net Income-$83.58M$31.83M$3.26B$265.56M7 Day Performance-1.09%1.80%2.11%1.98%1 Month Performance41.23%4.36%5.12%1.33%1 Year Performance-54.65%11.44%31.25%21.15% Korro Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KRROKorro Bio1.3768 of 5 stars$20.04-2.5%$86.83+333.3%-55.3%$188.20M$6.28M-2.0670TNGXTango Therapeutics1.9365 of 5 stars$7.22+6.6%$10.33+43.1%-32.6%$753.23M$42.07M-5.4390Insider TradeBGMBGM GroupN/A$8.15+7.7%N/A+28.5%$735.97M$25.10M0.00298MNMDMind Medicine (MindMed)2.8934 of 5 stars$9.75+1.5%$24.71+153.5%+53.2%$731.21MN/A-6.3740Positive NewsPHATPhathom Pharmaceuticals2.682 of 5 stars$10.10-1.4%$17.50+73.3%-15.6%$726.46M$55.25M-2.14110AMLXAmylyx Pharmaceuticals3.5 of 5 stars$7.99-0.1%$11.75+47.1%+273.0%$713.34M$87.37M-3.20200News CoveragePositive NewsDAWNDay One Biopharmaceuticals2.515 of 5 stars$6.81+0.9%$25.33+272.0%-50.8%$691.42M$131.16M-7.1760News CoverageInsider TradePROKProKidney3.7833 of 5 stars$2.54+7.6%$6.25+146.1%-2.9%$690.77M$80K-4.463News CoverageShort Interest ↓DNTHDianthus Therapeutics1.0963 of 5 stars$20.96+1.1%$53.00+152.9%-17.1%$667.59M$6.24M-6.4580Analyst ForecastHigh Trading VolumeGHRSGH Research2.739 of 5 stars$12.67-0.9%$32.00+152.6%+17.1%$665.44MN/A-17.1210Positive NewsMRVIMaravai LifeSciences4.0293 of 5 stars$2.57-1.5%$5.75+123.7%-72.8%$664.66M$259.18M-1.89610Options Volume Related Companies and Tools Related Companies Tango Therapeutics Alternatives BGM Group Alternatives Mind Medicine (MindMed) Alternatives Phathom Pharmaceuticals Alternatives Amylyx Pharmaceuticals Alternatives Day One Biopharmaceuticals Alternatives ProKidney Alternatives Dianthus Therapeutics Alternatives GH Research Alternatives Maravai LifeSciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KRRO) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Korro Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Korro Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access